TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03743766
Drug: Relatlimab + Nivolumab
Normalized name: nivolumab / relatlimab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination (Relatlimab + Nivolumab) therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV.
Study: NCT02511327
Drug: Infant pertussis vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants receive pertussis vaccines according to the national recommended schedule
Study: NCT01484080
Drug: BIBF + Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Priming Period:~Oral BIBF 1120 will be administered during 2 weeks at the dose determined during the phase-I part that can be combined safely with weekly paclitaxel, on a continuous schedule for 14 days.~One week washout is planned before starting the treatment phase.~Treatment Phase:~Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 + BIBF 1120 recommended dose bid po days 1-21 q 21 days. (BIBF 1120 morning dose is skipped on the paclitaxel administration days).
Study: NCT01484080
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 q 21 days. A total of 4 cycles will be administered in both arms.
Study: NCT02532335
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: active drug
Study: NCT03193047
Drug: bempedoic acid 180mg
Normalized name: BEMPEDOIC ACID 180MG TAB
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy
Study: NCT03746587
Drug: Arimoclomol
Normalized name: arimoclomol
DrugBank: Arimoclomol (DB05025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arimoclomol in 3 different dosages
Study: NCT03193047
Drug: evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly PCSK9i (evolocumab) background therapy
Study: NCT01429844
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus therapy was started immediately after transplantation with a continuous intravenous infusion of 0.01-0.03 mg/kg/d. After extubation, the mode of delivery was switched to oral administration (b.i.d.) with doses of 0.05-0.3 mg/kg/d. Tacrolimus doses were adjusted to trough levels. Target C0 (trough) levels were 10-15 ng/ml for the first 3 months after transplantation and 8-12 ng/ml thereafter with dose adjustments according to patient outcome.
Study: NCT01429844
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine therapy was started immediately after transplantation with a continuous intravenous infusion of 1-3 mg/kg/d. After extubation the mode of delivery was switched to oral administration (b.i.d. or t.i.d.) with doses of 4-18 mg/kg/d. Cyclosporine doses were adjusted to C0 or C2 levels according to local practice. Target trough levels were 200 - 300 ng/ml for the first 3 months after transplantation and 150 - 200 ng/ml thereafter.
Study: NCT02221648
Drug: AbobotulinumtoxinA Treatment
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Subjects receive intervention injections with the study drug arbobotulinumtoxinA.
Study: NCT00184938
Drug: morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00184938
Drug: naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00184938
Drug: Technetium-TC99m-labeled Annexin A5
Normalized name: TECHNETIUM TC99M TETROFOSMIN
DrugBank: Tetrofosmin (DB11180)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00226473
Drug: Cisplatin, Vindesine, Dacarbazine (drugs)
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03629873
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide 30mg po d-7、-4、0、3; Carmustine 300mg/m\^2 IVD d-6; Etoposide 150mg/m\^2/d qd IVD d-5\~-2; Cytarabine 150mg/m\^2 q12h IVD d-5\~-2; Cyclophosphamide 1.0g/m\^2/d qd IVD d-5\~-2
Study: NCT01276379
Drug: FOLFIRI (m)
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~* Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~* l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.~* One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~* 5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.
Study: NCT01276379
Drug: FOLFOX-6 (m)
Normalized name: 6-amyl-m-cresol
DrugBank: Amylmetacresol (DB13908)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~* Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~* l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.~* One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~* 5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.
Study: NCT01276379
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: - 500 mg/m2 i.v. Every 2 weeks.
Study: NCT01282476
Drug: Panobinostat with Rituximab
Normalized name: Panobinostat
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m\^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
Study: NCT02711176
Drug: Nexium
Normalized name: Nexium
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in experimental group will receive the 14 day single dose of Nexium 40 mg daily
Study: NCT00371956
Drug: raloxifene
Normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/day
Study: NCT03899857
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be added to standard of care
Study: NCT02711176
Drug: Lanzol
Normalized name: ethanol
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in active comparator group will receive the 14 day lansoprazole (Lanzol) 30 mg twice daily
Study: NCT03701880
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential
Study: NCT03701880
Drug: Bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bisoprolol is beta-blocker
Study: NCT00149396
Drug: NV1020
Normalized name: NV1020
DrugBank: NV1020 (DB04969)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NV1020 dose levels: 3x10\^6, 1x10\^7, 3x10\^7, and 1x10\^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks
Study: NCT03287076
Drug: Exenatide Injection
Normalized name: exenatide Injection
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset
Study: NCT01554982
Drug: ferric citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sulfate (DB11171)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose based on monthly serum phosphorus levels with goal of 3.5-5.5 mg/dL for all patients.
Study: NCT03639246
Drug: AVB-S6-500
Normalized name: AVB-S6-500
DrugBank: Batiraxcept (DB17522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVB-S6-500 is experimental drug
Study: NCT03639246
Drug: Paclitaxel (Pac)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel is active comparator
Study: NCT00062348
Drug: sodium borocaptate
Normalized name: Borocaptate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02236312
Drug: Botulinum Toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT01168921
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose 75 mg by mouth (PO) daily for 28 day cycle
Study: NCT00327717
Drug: Zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.
Study: NCT00719160
Drug: esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
Study: NCT03063736
Drug: Entolimod
Normalized name: Entolimod
DrugBank: Entolimod (DB12304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
Study: NCT00516100
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MTD of bortezomib administered Days 1 and 8 plus 500 mg/m2 pemetrexed on day 1, every three weeks.
Study: NCT03126786
Drug: IVT aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IVT aflibercept \[2 mg/0.05 mL\]
Study: NCT03126786
Drug: Sham SC
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham SC
Study: NCT03126786
Drug: SC CLS-TA
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLS-TA \[4 mg/100 μL\] SC injection
Study: NCT02342392
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.
Study: NCT01679392
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unilateral, single shot, ultrasound-guided, transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
Study: NCT03128619
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03128619
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03128619
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00730990
Drug: PET Scan with PF-03654746
Normalized name: Pet-ema
DrugBank: PF-03654746 (DB12201)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention.
Study: NCT00730990
Drug: PET Scan with PF-03654746
Normalized name: Pet-ema
DrugBank: PF-03654746 (DB12201)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If none of the data from the previous interventions are informative, then: 3) an additional 3 patients will receive 2 scans on Day 1 and 1 scan on Day 2 following three different doses of PF-0365476. Doses will be determined based upon the outcomes of the previous interventions.
Study: NCT04211012
Drug: Toripalimab plus Nab-Paclitaxel +/- cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toripalimab injection (JS001): 240mg, i.v.gtt, q3w; Nab-Paclitaxel: 260mg/m2, i.v.gtt, q3w Cisplatin: total dosage of 70 mg/m2 i.v.gtt, q3w，, complete all doses within the first 2 days of each cycle.~Study treatment will be continued until disease progression or intolerable toxicity, or withdrawal at the discretion of the investigator or the subject, loss to follow-up, or initiation of other anti-cancer therapy, or death, whichever occurs first. Toripalimab will be administered no more than 2 years,and nab-paclitaxel with or without cisplatin will be administered up to 6 cycles.. If the subject is intolerable to cisplatin treatment according to the investigator's judgment, JS001 + Nab-Paclitaxel may be dosed.~Dosing sequence: Toripalimab, Nab-Paclitaxel, cisplatin
Study: NCT00991289
Drug: Nitazoxanide (NTZ)
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg twice daily, taken orally with food
Study: NCT00991289
Drug: Pegylated interferon alfa-2a (PEG)
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 micrograms via subcutaneous injection once weekly
Study: NCT00991289
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weight-based dosing; 1,000 mg daily, taken orally, for people weighing less than 75 kg or 1,200 mg for people weighing at least 75 kg.
Study: NCT01954238
Drug: GCC-4401C
Normalized name: Oristar gcc
DrugBank: Glyceryl monocaprylate (DB19362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease.~* The dose selection for this clinical study was based on the safety, Pharmacokinetics and Pharmacodynamics results of the single dose study.~* GCC-4401C was well tolerated in the single ascending dose study up to the highest single oral dose administered of 80 mg from 2.5 mg in 48 subjects.~* The study consists of five cohorts (10 mg, 20 mg, 40 mg, 60 mg, and 80 mg) with eight subjects per cohort.~* In the 20 mg cohort, six additional subjects will receive rivaroxaban (Xarelto®) 20 mg as an active comparator in open-label fashion.
Study: NCT01954238
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban (Xarelto®) 20 mg tablets for oral administration IMP, placebo and comparator will be administered the same time points. The comparator will be administered open-label 30 minutes after a standard breakfast.
Study: NCT01211145
Drug: Zolmitriptan
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg nasal spray
Study: NCT01211145
Drug: Zolmitriptan
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg nasal spray
Study: NCT01211145
Drug: Zolmitriptan
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5.0 mg nasal spray
Study: NCT01234597
Drug: INSULIN GLARGINE (HOE901)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT01234597
Drug: INSULIN GLULISINE (HMR1964)
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
Study: NCT01442662
Drug: pazopanib + gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
Study: NCT01518569
Drug: ulinastatin
Normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ulinastatin 5000 unit/kg iv before the initiation of CPB
Study: NCT03292185
Drug: insulin degludec/liraglutide
Normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.
Study: NCT03292185
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 17 U Insulin Degludec, single dose administration under the skin in the thigh.
Study: NCT03292185
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.6 mg Liraglutide, single dose administration under the skin in the thigh
Study: NCT04842370
Drug: PHI-101
Normalized name: PHI-101
DrugBank: PHI-101 (DB17237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHI-101, oral, once-daily administration, consisting of 28-days per 1 cycle
Study: NCT01373151
Drug: BMS-945429 Placebo
Normalized name: BMS-945429
DrugBank: Clazakizumab (DB12849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only
Study: NCT03421379
Drug: Glucagon Nasal Powder
Normalized name: glucagon Nasal Powder
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intranasally
Study: NCT03421379
Drug: Glucagon Hydrochloride Solution
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IM
Study: NCT00120705
Drug: darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04058028
Drug: Rozibafusp Alfa
Normalized name: Rozibafusp Alfa
DrugBank: Rozibafusp Alfa (DB19233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rozibafusp Alfa will be presented in 5 mL glass vial
Study: NCT01373151
Drug: Adalimumab Placebo
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
Study: NCT01373151
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks
Study: NCT04058028
Drug: Placebo for Rozibafusp Alfa
Normalized name: Rozibafusp Alfa
DrugBank: Rozibafusp Alfa (DB19233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Rozibafusp Alfa will be presented in 5 mL glass vial
Study: NCT00730990
Drug: PET Scan with PF-03654746
Normalized name: Pet-ema
DrugBank: PF-03654746 (DB12201)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2 of the study will have 3 possible interventions:~1) 3 subjects in Cohort 2 will receive 2 scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746 (0.5 mg, 1.5 mg, 4 mg).
Study: NCT03840837
Drug: Rivastigmine transdermal patch
Normalized name: rivastigmine Transdermal Product
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Titration of transdermal rivastigmine, as per arm description.
Study: NCT02011958
Drug: Liposomal Amphotericin B
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/kg total dose: IV infusion of 5mg/kg per day on day 1 to 5, 10,17,24 (when administered as a monotherapy)~30 mg/kg total dose: IV infusion 5 mg/kg per day on day 1, 3, 5, 7, 9, 11 (when administered in combination with Miltefosine)
Study: NCT02186600
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)
Study: NCT02186600
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.
Study: NCT00296855
Drug: Vasovist (BAY86-5283, MS-325)
Normalized name: MS-1819
DrugBank: Gadofosveset trisodium (DB06705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
Study: NCT02186600
Drug: Risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronate 35 mg orally will be ingested weekly by subjects in Risedronate group.
Study: NCT02011958
Drug: Miltefosine
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally taken every day during 28 days~* 1 x 50 mg capsule per day if the patient weights less or equal to 25 kg~* 2 x 50 mg capsules per day if the patient weights more than 25 kg (1 capsule in the morning / 1 capsule in the evening)
Study: NCT00437125
Drug: Duloxetine hydrochloride
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks
Study: NCT01397422
Drug: ADS-5102 (extended release amantadine HCl)
Normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsules to be administered once daily at bedtime, for 8 weeks
Study: NCT03311464
Drug: adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study drug will be administered subcutaneously.
Study: NCT02801032
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose, 20 mg capsule p.o. minimum one week apart from placebo.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention.
Study: NCT01939730
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.